QuidelOrtho Corp
QDEL29.810USD
+0.860+2.97%
收盘 12/22, 16:00（美东）报价延迟15分钟
2.02B总市值
亏损市盈率 TTM
关于 QuidelOrtho Corp 公司
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
QuidelOrtho Corp简介
公司代码QDEL
公司名称QuidelOrtho Corp
上市日期Feb 01, 1991
CEOBlaser (Brian J)
员工数量6600
证券类型Ordinary Share
年结日Feb 01
公司地址9975 Summers Ridge Road
城市SAN DIEGO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92121
电话18585521100
网址https://www.quidelortho.com/
公司代码QDEL
上市日期Feb 01, 1991
CEOBlaser (Brian J)
QuidelOrtho Corp公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9.68%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+75.18%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
32.03K
+8.95%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
15.02K
+5.26%
Mr. Brian J. Blaser
Mr. Brian J. Blaser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.45K
--
Mr. John R. Chiminski
Mr. John R. Chiminski
Independent Director
Independent Director
2.52K
--
Sergio Gadaleta
Sergio Gadaleta
Senior Vice President - Clinical and Regulatory Affairs
Senior Vice President - Clinical and Regulatory Affairs
--
--
Devon Burek
Devon Burek
Senior Vice President - Global Quality
Senior Vice President - Global Quality
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9.68%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+75.18%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
32.03K
+8.95%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
15.02K
+5.26%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Labs
369.70M
60.22%
Immunohematology
132.30M
21.55%
Point-of-Care
93.00M
15.15%
Donor Screening
13.30M
2.17%
Molecular Diagnostic Solutions
5.60M
0.91%
地区USD
名称
营收
占比
North America
310.70M
50.61%
Other
132.50M
21.58%
EMEA
87.30M
14.22%
China
83.40M
13.59%
业务
地区
业务USD
名称
营收
占比
Labs
369.70M
60.22%
Immunohematology
132.30M
21.55%
Point-of-Care
93.00M
15.15%
Donor Screening
13.30M
2.17%
Molecular Diagnostic Solutions
5.60M
0.91%
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
16.21%
BlackRock Institutional Trust Company, N.A.
13.72%
The Vanguard Group, Inc.
11.19%
Rubric Capital Management LP
6.83%
Fidelity Management & Research Company LLC
6.54%
其他
45.52%
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
16.21%
BlackRock Institutional Trust Company, N.A.
13.72%
The Vanguard Group, Inc.
11.19%
Rubric Capital Management LP
6.83%
Fidelity Management & Research Company LLC
6.54%
其他
45.52%
股东类型
持股股东
占比
Investment Advisor
68.41%
Investment Advisor/Hedge Fund
35.84%
Hedge Fund
14.73%
Research Firm
2.25%
Pension Fund
1.07%
Individual Investor
0.95%
Private Equity
0.76%
Bank and Trust
0.61%
Sovereign Wealth Fund
0.52%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
656
79.44M
116.95%
-23.17M
2025Q2
684
78.51M
115.63%
-21.42M
2025Q1
726
76.59M
113.26%
-21.60M
2024Q4
747
75.07M
111.30%
-13.02M
2024Q3
744
73.58M
109.44%
-4.02M
2024Q2
767
70.18M
104.79%
-7.57M
2024Q1
799
67.05M
100.24%
-5.28M
2023Q4
828
68.21M
102.09%
-2.95M
2023Q3
842
70.19M
105.17%
-4.01M
2023Q2
860
68.99M
103.61%
-6.94M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
T. Rowe Price Investment Management, Inc.
11.14M
16.4%
-310.96K
-2.72%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
9.28M
13.67%
+1.73M
+22.86%
Jun 30, 2025
The Vanguard Group, Inc.
7.77M
11.44%
+1.04M
+15.55%
Jun 30, 2025
Rubric Capital Management LP
4.64M
6.83%
-1.50M
-24.47%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.56M
3.76%
+1.30M
+103.23%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.51M
3.69%
+691.35K
+38.04%
Jun 30, 2025
Newtyn Management, LLC
1.71M
2.51%
+490.67K
+40.38%
Jun 30, 2025
State Street Investment Management (US)
2.70M
3.98%
+510.29K
+23.29%
Jun 30, 2025
Invesco Advisers, Inc.
1.33M
1.96%
-2.27M
-63.07%
Jun 30, 2025
American Century Investment Management, Inc.
1.92M
2.82%
+327.00K
+20.58%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
State Street SPDR S&P Health Care Equipment ETF
1.75%
Invesco S&P SmallCap Health Care ETF
1.12%
Ballast Small/Mid Cap ETF
0.94%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.56%
JPMorgan Fundamental Data Science Small Core ETF
0.35%
State Street SPDR S&P 600 Small Cap Value ETF
0.26%
Avantis US Small Cap Value ETF
0.26%
iShares S&P Small-Cap 600 Value ETF
0.25%
iShares U.S. Medical Devices ETF
0.22%
State Street SPDR S&P SmallCap 600 ESG ETF
0.19%
查看更多
State Street SPDR S&P Health Care Equipment ETF
占比1.75%
Invesco S&P SmallCap Health Care ETF
占比1.12%
Ballast Small/Mid Cap ETF
占比0.94%
First Trust Nasdaq Lux Digi Health Solutions ETF
占比0.56%
JPMorgan Fundamental Data Science Small Core ETF
占比0.35%
State Street SPDR S&P 600 Small Cap Value ETF
占比0.26%
Avantis US Small Cap Value ETF
占比0.26%
iShares S&P Small-Cap 600 Value ETF
占比0.25%
iShares U.S. Medical Devices ETF
占比0.22%
State Street SPDR S&P SmallCap 600 ESG ETF
占比0.19%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
QuidelOrtho Corp的前五大股东是谁？
QuidelOrtho Corp 的前五大股东如下：
T. Rowe Price Investment Management, Inc.持有股份：11.14M，占总股份比例：16.40%。
BlackRock Institutional Trust Company, N.A.持有股份：9.28M，占总股份比例：13.67%。
The Vanguard Group, Inc.持有股份：7.77M，占总股份比例：11.44%。
Rubric Capital Management LP持有股份：4.64M，占总股份比例：6.83%。
Fidelity Management & Research Company LLC持有股份：2.56M，占总股份比例：3.76%。
T. Rowe Price Investment Management, Inc.持有股份：11.14M，占总股份比例：16.40%。
BlackRock Institutional Trust Company, N.A.持有股份：9.28M，占总股份比例：13.67%。
The Vanguard Group, Inc.持有股份：7.77M，占总股份比例：11.44%。
Rubric Capital Management LP持有股份：4.64M，占总股份比例：6.83%。
Fidelity Management & Research Company LLC持有股份：2.56M，占总股份比例：3.76%。
QuidelOrtho Corp的前三大股东类型是什么？
QuidelOrtho Corp 的前三大股东类型分别是：
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
有多少机构持有QuidelOrtho Corp(QDEL)的股份？
截至2025Q3，共有656家机构持有QuidelOrtho Corp的股份，合计持有的股份价值约为79.44M，占公司总股份的116.95%。与2025Q2相比，机构持股有所增加，增幅为1.32%。
哪个业务部门对QuidelOrtho Corp的收入贡献最大？
在FY2025Q2，Labs业务部门对QuidelOrtho Corp的收入贡献最大，创收369.70M，占总收入的60.22%。
